Lumen Biosciences Brian Finrow breaks down Chinas biotech playbook and explores ways the U.S. can adapt it for its own continued success.

Women leaders are driving success in life sciences but remain underrepresented and undervalued. That needs to change, writes ...

Part one of a two-part series on FDA Commissioner Martin Makary, M.D.s comments at the Gailen Forum in New York City on October 30, 2025.

Pay close attention to contract language regarding royalties, including when and where patents expire, or pay the price, ...

Believing “good companies are bought, not sold” does not reflect the reality of most life sciences transactions, write ...

On this week's Business of Biotech episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of Life Science Leader's ...

The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and ...

Since clinical trials have become increasingly complex with more data being collected, this consequently puts more pressure on sponsors to improve efficiencies while still maintaining quality.

AI is becoming increasingly sophisticated, taking on responsibilities that were once exclusive to human beings. However, there are also disadvantages posed by ethical ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

The False Claims Act (FCA) and the Anti-Kickback Statute (AKS) are two of the Department of Justice’s (DOJ) primary tools when it comes to fighting fraud. Originally enacted during the Civil War to ...